X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2021/10/04/2307863/0/en/NKMax-Announces-SNK01-Abstract-Accepted-for-Presentation-at-the-Society-for-Immunotherapy-of-Cancer-SITC-2021-Annual-Meeting.html
https://www.globenewswire.com/news-release/2021/10/04/2307863/0/en/NKMax-Announces-SNK01-Abstract-Accepted-for-Presentation-at-the-Society-for-Immunotherapy-of-Cancer-SITC-2021-Annual-Meeting.html
https://www.globenewswire.com/news-release/2021/04/13/2209245/0/en/NKMax-and-Merck-KGaA-Darmstadt-Germany-Expand-Clinical-Collaboration-to-Include-Phase-I-IIa-Trial-Investigating-the-Combination-of-SNK01-with-ERBITUX-cetuximab-in-Metastatic-NSCLC.html
http://www.globenewswire.com/news-release/2021/04/02/2203854/0/en/NKMax-America-Announces-Corporate-Name-Change-to-NKGen-Biotech.html#:~:text=SANTA%20ANA%2C%20Calif.%2C%20April,which%20the%20Company%20believes%20best
https://www.affimed.com/affimed-and-nkmax-america-announce-fda-clearance-of-ind-application-to-study-the-combination-of-afm24-an-egfr-targeted-innate-cell-engager-with-snk-01-natural-killer-cell-therapy-in-solid-tumors/
https://www.globenewswire.com/news-release/2020/08/31/2086394/0/en/NKMax-America-Receives-FDA-Clearance-to-Amend-its-Current-Phase-I-Monotherapy-Trial-to-Include-an-Additional-New-Cohort-of-SNK01-Checkpoint-Inhibitor-in-Refractory-Solid-Tumors.html
https://www.globenewswire.com/news-release/2020/06/02/2042170/0/en/NKMax-America-Receives-FDA-Clearance-of-IND-for-Phase-I-2a-Trial-of-their-Natural-Killer-Cell-Therapy-SNK01-in-Combination-with-Trastuzumab-or-Cetuximab-for-the-Treatment-of-Advanc.html
Market Place
Share 
